Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 29, 2009
Rituximab May Offer Hope To Severe Graves' Eye Disease Patients
November 29, 2009There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.
This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.
Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.
Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.5±0.8 to 1.3±0.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.
Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 24±3.7 mm before therapy and 23.6±3.7 mm after therapy; P = 0.17).
"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."
Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.
Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.
"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.
Source
Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029
University of Michigan Health System Newsroom
Archive issues: (50)
Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 [15] 16 17
November 2, 2009 | Ground Beef Recall, Meat Sold in 8 StatesConsumers are warned that a new beef recall is in effect. Fairbank Farms issued a voluntary beef recall on Saturday, October 31, specifically for its line of fresh ground beef products sold in eight states. Thus far one person, a New Hampshire resident, has reportedly died after consuming the recalled beef, which is ...
Can Chewing Gum Really Help You Lose Weight? | November 1, 2009Chewing sugar-free gum may help you lose weight, according to a nutrition professor at the University of Rhode Island. The new study notes that chewing gum can help to reduce the number of calories you eat and increase your energy output. According to the US Mint Industry, half of all Americans chew gum, and the average American chews about 300 ...
October 10, 2009 | Who Is To Blame For The Swine Flu Vaccine Problems?Washington (SmartAboutHealth) - One thing has become perfectly clear over the past few weeks, there is a major problem in the U.S. in regards to getting the H1N1 swine flu vaccine out to the public, but who is to blame? The swine flu continues to run rampant all across the U.S. and the delivery of the H1N1 swine flu vaccine is failing to keep up. Week after week the deliveries of the vaccine fall behind in regards to when they were ...
Related articles:
Chronic prostatitis/chronic pelvic pain syndrome - diagnosis
There are no definitive diagnostic tests for CP/CPPS. This is a poorly understood disorder, even though it accounts for 90%-95% of prostatitis diagnoses. It is found in men of any age, with the peak onset in the early 30s. CP/CPPS may be inflammatory (Category IIIa) or non-inflammatory (Category IIIb), based on levels of pus cells in ...Section: Prostatitis
Chronic prostatitis/chronic pelvic pain syndrome - pharmacological treatment
There is a substantial list of medications used to treat this disorder. Some of them are: Quercetin has shown effective in a randomized, placebo-controlled trial in chronic prostatitis using 500 mg twice a day for 4 weeks Subsequent studies showed that quercetin, a mast cell inhibitor, reduces inflammation and oxidative stress in the prostate. Pollen extract (Cernilton) has also been shown effective in randomized placebo controlled trials. At least one study suggests that ...Section: Prostatitis
Acute prostatitis - treatment
Antibiotics are the first line of treatment in acute prostatitis. Antibiotics usually resolve acute prostatitis infections in a very short time. Appropriate antibiotics should be used, based on the microbe causing the infection. Some antibiotics have very poor penetration of the prostatic capsule, others, such as Ciprofloxacin, Co-trimoxazole and ...Section: Prostatitis